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Abstract
Background: Statins are used for treatment of hypercholestremia. Common adverse reports associated with use of
statins are generalized bodyache, rhabdomyolysis, muscles weakness and gastrointestinal disorders. The current
work is an attempt to explain how smooth muscles of gastrointestinal tissues are affected by the current statins
(Simvastatin, atorvastatin, fluvastatin and rosuvastatin).
Methods: Effects of the current statins were studied on spontaneous activity of isolated rabbits’ jejunal
preparations. Different molar concentrations (10−12–10−2M) of the statins were applied on spontaneously
contracting rabbits’ jejunal preparations. As statins relaxed spontaneous activity, so we tested the statins on KCl
(80 mM) induced contractions in similar test concentrations. Positive relaxant statins were tested again through
construction of Calcium Concentration Response Curves (CCRCs) in the absence and presence of the statins using
verapamil, a standard calcium channel blocker. CCRCs of statins were compared with CCRCs of verapamil.
Results: Simvastatin, atorvastatin, fluvastatin and rosuvastatin relaxed the spontaneous and KCl-induced
contractions. IC50 for simvastatin on spontaneous rabbit’s jejunal preparations is −5.08 ± 0.1 Log 10 M. Similarly, IC50
for KCl-induced contractions is −4.25 ± 0.01 Log 10 M. Mean IC50 (Log 10 M) for atorvastatin on spontaneous
rabbit’s jejunal preparations and KCl-induced contractions are −5.19 ± 0.07 and −4.37 ± 0.09, respectively. Fluvastatin
relaxed spontaneous activity of rabbits’ jejunal preparations with an IC50 (Log 10 M) −4.5 ± 0.03. Rosuvastatin
relaxed spontaneous as well as KCl (80 mM) induced contractions with respective IC50 (Log 10 M) −3.62 ± 0.04 and
−4.57 ± 0.06. In case of CCRCs, tissues pre-treated with 4.6 μg/ml of simvastatin, have IC50 = −1.84 ± 0.03 [log (Ca++)
M] vs control IC50 = −2.54 ± 0.04 [log (Ca
++) M]. Similarly, atorvastatin, fluvastatin and rosuvastatin produced
significant right shift in IC50 for CCRCs (P ≤ 0.05). In case of verapamil, IC50 for control curves is −2.45 ± 0.06 [log
(Ca ++) M], while IC50 in presence of verapamil (0.1 μM) is −1.69 ± 0.05 [log (Ca ++) M]. Statins produced right shift in
the IC50 of CCRCs. The effects of statins are like that of effects of verapamil, a standard calcium channel blocker.
Conclusions: Our findings suggest that current statins have calcium antagonistic effects that act on voltage gated
calcium channels that may provide a rationale for cause muscle weakness and gastrointestinal disorders.
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Background
There are very hot discussions about the safety profile
and role of statins use in low risk cardiovascular pa-
tients. Even stake holders in health professions ask for
an impartial review of statins especially in patients who
are at low risk [1]. Statins are therapeutically effective
lipid lowering drugs, which are used to reduce blood
cholesterol in patients with hypercholestremia [2]. Sta-
tins reduce the development of atherosclerosis and pre-
vent formation of atheromatous lesion [3]. Statins
inhibit the enzyme HMG-CoA reductase and prevents
the de novo synthesis of cholesterol as well [4]. Statins
decrease intracellular cholesterol level, which increases
the LDL receptors that can combine and internalize cir-
culating LDLs. Consequently plasma cholesterol level is
reduced by inhibiting cholesterol synthesis and raise ca-
tabolism of LDLs [5]. It is explicit that statins decrease
cholesterol in addition to have pleotropic action [6].
Three lipid lowering drugs i.e. lovastatin, simvastatin
and pravaststin were approved for marketing in 1990 [7,
8]. Statins valuable effects were seen in cardiac patients
[9]. With passage of time, its adverse effects started
appearing. Following administration of normal doses,
statins are quickly absorbed and gain peak plasma con-
centrations within 4 h. They are metabolised by Cyto-
chrome P450, which is composed of 30 isoenzymes. [10,
11]. Fluvastatin is metabolized through CYP2C9 and
drugs like fluconazole and diclofenac (inhibitors of
CYP2C9) interact to raise plasma levels of the statins
[12]. Common adverse effects of statins are muscle pain
and weakness, which can progress to rhabdomyolysis
[13, 14]. Myositis, myalgia and cataract [15] are mostly
caused by fluvastatin and simvastatin. Cerivastatin was
withdrawn from market because of myotoxicity pro-
duced in most of the patients [16]. Most common un-
wanted effects of statin on gastrointestinal system are
constipation, dyspepsia, abdominal pain, nausea, vomit-
ing, heartburn and flatulence [15]. Smooth muscles’ con-
traction of GIT is due to calcium influx, which is
regulated by calmodulin mechanism. Stimulating fibres
in myosin filaments cause to develop attractive forces
between actin and myosin filaments which is responsible
for smooth muscles contractions. Total cholesterol level
in human body is decreased by regulating cholesterol
quantity in intestinal wall due to reducing Acetyl Co
acyltransferase enzyme [17]. Statins also deregulate cal-
cium channels that stimulate differentiated phenotype of
vascular smooth muscle cells, as a consequence, reacti-
vate calcium influx pathway and also upregulate L-type
calcium channels, where calcium channel blocker effect
is synergized in vascular cells [18]. But this upregulation
takes time to develop and was studied in cell lines. It
was also observed in animal study that using long term
statins in hypertensive animals normalized blood
pressure and wall of blood vessels [19]. Perhaps, this
may be attributed to reports which say that smooth
muscles’ cell migration, proliferation and invasion was
inhibited by statins due to preventing isoprenoid path-
ways that subsequently inhibit Rhoprenylation of smooth
muscles’ cells [20]. As there are reports for GI upsets
with statins in start of therapy, hence we designed
current study to test the direct effects of statins on iso-
lated rabbits’ jejunal preparations. Thus our objective
was to check the current statins for possible inhibitory
effects on voltage gated calcium channels that may de-
scribe possible rationale for gastrointestinal disorders.
Study setting
The study was carried out in Department of Pharmacol-
ogy, Institute of Basic Medical Sciences, Khyber Medical
University, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Methods
Effects of current statins on isolated rabbits’ jejunal
preparation
The aim of the current work is to find out possible ef-
fects of some current statins (simvastatin, atorvastatin,
fluvastatin and rosuvastatin) on isolated rabbits’ jejunal
preparations.
Drugs and standards
Analytical grade chemicals were used in the experi-
ments. Acetylcholine was purchased from BDH, Poole,
England, which was used for maintenance of isolated tis-
sues. Raw materials of rosuvastatin and atorvastatin as
calcium salts were obtained from Ferozsons Laboratories
Pvt. Ltd. Nowshera, Pakistan. Raw material of simva-
statin was taken from Polyfine Pharmaceutical Industry,
Peshawar. Fluvastatin of Novartis Pharma were pur-
chased from local market of Peshawar, Pakistan. Raw
materials, which had poor solubility in Tyrode’s solu-
tions, were suspended in 0.01 % Carboxy Methyl Cellu-
lose (CMC). However, a negative control of 0.01 % of
CMC in deionized water was run to rule out any pos-
sible effects of CMC. All solutions and suspensions were
freshly prepared on the same days of experiments.
Animals
Local breed rabbits weighing (1.5–2.0 kg; either sex)
were used in the experiments. They were kept in animal
house under controlled environment at Institute of Basic
Medical Sciences, Khyber Medical University, Peshawar,
Pakistan. The animals ware fasted overnight before the
days of experiments. They had free access to water. The
study protocols were approved by the Advanced Study &
Research Board and Ethical Board (Approval No. Dir/
KMU/-EB/SE/000138) of the Khyber Medical University,
Peshawar, Pakistan.
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Data recording
Intestinal responses were recorded using Force Trans-
ducer (Model No: MLT 0210/A Pan Lab S.I), connected
through an amplifier FE 221 attached with four channels
Power Lab (Model No: 4/25 T) AD Instruments,
Australia. Lab Chart 7 was used to record and interpret
the intestinal responses of isolated jejunal preparations.
Physiological solutions used in the experiments
Normal Tyrode’s solution, Potassium Normal (Ca++ free)
Tyrode’s solution and Potassium Rich (Ca++ free) Tyr-
ode’s solutions were used in the experiments. All solu-
tions were prepared in deionized water on the same day
of experiments.
Effects of statins on spontaneous rabbits’ jejunal
preparations
Abdomens of overnight fasted rabbits were opened.
Their jejunums were removed and placed in petri dishes
containing Tyrode’s solution. The tissues were main-
tained with constant supply of carbogen gas (95 % O2,
5 % CO2) [21]. Pieces of about 1.5 cm were cut from the
jejunums and mounted in organ bath containing Tyr-
ode’s solution already maintained with carbogen gas
(95 % O2, 5 % CO2) on 37 ± 1 °C. The composition of
Tyrode’s solution was (mM) KCl 2.7, NaH2PO4 0.4,
NaCl 136.9, Glucose 5.6, MgCl2 1.1, CaCl2 1.8, NaHCO3
11.9 on pH 7.4. Test concentrations of current statins
were prepared in deionized water as mentioned above.
The statins were added in cumulative manner to the
organ bath in test concentrations Log10 (1 × 10−12–1 ×
10−3) M which entail their plasma levels. The test sam-
ples were applied in a period of 1 min gap. Effects on
spontaneous jejunal preparations were recorded as per
our reported procedures [22, 23]. Earlier, tissues were
stabilized for a period of 30 min before testing the
statins.
Effects of statins on KCl (80 mM)-induced contractions
As KCl-depolarizes the tissues and keep the tissues in
sustained contractions, hence any relaxing effects are
usually, but not necessarily, regarded as to follow voltage
gated calcium channels. So we tested the statins on KCl-
induced contraction in similar equimolar concentrations
Log10 (1 × 10−12–1 × 10−3) M in cumulative manners.
Their effects are recorded [22, 24]. IC50 were calculated
using Graph Pad Prism.
Effects of statins on calcium concentration response
curves (CCRCs)
For confirmation of involvement of voltage gated cal-
cium channels, we constructed CCRCs in a range of cal-
cium concentration 1 × 10−4–256 × 10−4 M in absence
and presence of different concentrations of statins as per
our reported practice [23, 25, 26]. Verapamil was used
as standard calcium channel blocker [23, 25–27]. Briefly
describing the procedure, the tissues were maintained in
Tyrode’s solution. After stabilization of tissues, the tis-
sues were exposed to a series of wash with Tyrode’s Nor-
mal (calcium free) solution followed by exposure to K-
Rich Tyrode’s solution. K-Rich Tyrode’s solution com-
position was (mM) NaCl 91.04, KCl 50, NaH2 PO4 0.42,
MgCl2 1.05, EDTA 0.1, NaHCO3 11.90 and glucose 5.55.
This lead to decalcification of tissues. The temperature
was maintained on 37 ± 1 °C. Control CCRCs were con-
structed in absence of statins. Then CCRCs were con-
structed in presence of different concentrations of
statins following an incubation period of 1 h. Similarly,
curves were constructed in absence and presence of ver-
apamil, a standard calcium channel blocker. The CCRCs
were compared for any possible right shift.
Statistical analysis
Effects of test concentrations of statins on isolated rab-
bits’ jejunal preparations were plotted versus respective
concentrations of statins as dose repose curves using
Graph Pad Prism. Effects were expressed as % of control
maximum for spontaneous as well as KCl-induced con-
tractions. For CCRCs, control curves were drawn in
Graph Pad Prism. CCRCs were also drawn in presence
of respective statins concentrations. Data were analysed
using nonlinear regression (curve fit) method with built
in equation for sigmoidal dose response using Graph
Pad Prism. Two way ANNOVA was used to determine
the significances of concentration versus responses at
95 % CI with P < 0.05.
Results
Effects of statins on spontaneous and KCl-induced con-
tractions are shown in Fig. 1. Effects of simvastatin on
spontaneous activity of rabbits’ jejunal preparations and
KCl (80 mM) induced contractions are shown in Fig. 1a.
Decrease in spontaneous activity is evident on concen-
tration −6.15 Log 10[Simvastatin] M. IC50 value on
spontaneous rabbits’ jejunal preparations is −5.08 ± 0.1
Log 10[Simvastatin] M. Relaxant effects of simvastatin
was maximum (65 %) of control maximum on concen-
tration −3.4 Log10[Simvastatin] M. Similarly, KCl-
induced contractions were relaxed in concentration −5.2
Log 10[Simvastatin]M. Mean IC50 value of simvastatin
for KCl induced contraction Log 10[Simvastatin] M was
−4.25 ± 0.01 (Table 1). Similarly, atorvastatin effects on
spontaneous activity of rabbits’ jejunal preparations and
KCl (80 mM) induced contractions are shown in Fig. 1b.
Decrease in spontaneous activity was evident on concen-
tration −4.3 Log[Atorvastatin] M. Mean IC50 value on
spontaneous rabbit’s jejunal preparations and KCl-induced
contractions are −5.19 ± 0.07 Log 10[atorvastatin] M and
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−4.37 ± 0.09 Log 10[atorvastatin]M. Relaxant effect on
KCl induced contractions was maximum (70 %) in con-
centration −3.3 Log 10[atorvastatin] M.
Fluvastatin effects on spontaneous activity of rabbits’
jejunal preparations and KCl (80 mM) induced contrac-
tions are shown in Fig. 1d with respective mean IC50
values of −3.63 ± 0.04 Log 10[fluvastatin] M and −3.52 ±
0.02. Spasmolytic effect of fluvastatin was maximum on
concentration −3.3 Log 10[fluvastatin]M. Rosuvastatin
relaxed spontaneous as well as KCl (80 mM) induced
contractions with respective mean IC50 (Log 10[rosuvas-
tatin]M) of −3.62 ± 0.04 and −4.57 ± 0.06 Fig. 1c. De-
crease in spontaneous activity started in concentration
−5.2 Log 10[rosuvastatin]M. Maximum relaxing effects
on spontaneous and KCl-induced contractions were re-
spectively 70 and 40 % on −3.39 Log 10[rosuvastatin]M.
Fig. 1 To show the effect of a simvastatin, b atorvastatin, c rosuvastatin, d fluvastatin, and e verapamil on spontaneous and KCl-induced
contractions. (Effects is expressed as percent of control maximum, n = 5)
Table 1 To show the effects of current statins on spontaneous and 80mM KCl-induced contractions in isolated rabbits’ jejunal
preparations (n = 5)
Types of contractions Mean Log Molar IC50 of statins (Mean ± SD)
Simvastatin Atorvastatin Rosuvastatin Fluvastatin Verapamil
Spontaneous contractions −5.08 ± 0.1 −5.19 ± 0.07 −3.62 ± 0.04 −4.5 ± 0.03 −0.5 ± 0.01
KCl-induced contractions −4.25 ± 0.01 −4.37 ± 0.09 −4.57 ± 0.06 −3.52 ± 0.02 −1.43 ± 0.04
Ali et al. BMC Pharmacology and Toxicology  (2016) 17:43 Page 4 of 7
Verapamil relaxed both spontaneous and KCl-induced
contractions with respective IC50 (Log 10[Verapamil]M)
values of −0.5 ± 0.01 and −1.43 ± 0.04 (Fig. 1e).
Calcium channel blocking activity on Rabbits’ jejunal
preparations
Contractions in smooth muscles occur due to calcium
influx. Two types of Ca2+ channel are involved i.e. volt-
age dependent and receptor-linked Ca2+channels. Intes-
tinal contractions are due to cytosolic free calcium levels
which passes through voltage gated calcium channels in
sarcoplasmic reticulum [21, 25, 28, 29]. It has been re-
ported that KCl opens the voltage gated calcium chan-
nels. Thus an agent which relaxes the KCl-induced
contractions is considered to have calcium channel
blocking activity. But as reported that positive relaxing
effects on KCl-induced contraptions not always follow
inhibition of voltage gated calcium channels, hence,
construction of calcium concentration response curves
will testify with a right shift in the tissues or otherwise
[30].
As statins (simvastatin, atorvastatin, fluvastatin and
rosuvastatin) in different concentrations showed relaxing
properties both on spontaneous and KCl-induced con-
tractions, hence, we constructed CCRCs. Calcium chlor-
ide curves in the absence (control) and presence of test
samples of simvastatin, atorvastatin, fluvastatin and
rosuvastatin are shown in Fig. 2. According to Fig. 2a,
IC50 for control curve, in case of simvastatin, is −2.54 ±
0.04 [log (Ca ++) M]. While tissues pre-treated with
4.6 μg/ml of simvastatin, have IC50 = −1.84 ± 0.03 [log
(Ca ++) M]. Similarly, IC50 for atorvastatin, control curve
is−2.48 ± 0.06 [log (Ca ++) M]. In presence of 23.1 μg/ml
of atorvastatin, IC50 = −1.99 ± 0.04 [log (Ca
++) M]
(Fig. 2b). IC50 ([log (Ca
++) M]) value for control and in
presence of 9.6 μg/ml of fluvastatin are −2.11 ± 0.05 and
−1.56 ± 0.03, respectively (Fig. 2c). In presence of
Fig. 2 To show the effect of a simvastatin, b atorvastatin, c fluvastatin, d rosuvastatin, and e verapamil on calcium chloride curve compared to
that of the respective controls
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rosuvastatin 6.6 μg/ml value of IC50 = −2.17 ± 0.03, while
for control IC50 = −2.44 ± 0.03 [log (Ca
++) M] Fig. 2d.
IC50 values are shown in Table 2. In case of verapamil,
IC50 [log (Ca
++) M] for control curves is −2.45 ± 0.06,
while IC50 in presence of verapamil (0.1 μM= 45.46 μg/
ml) is −1.69 ± 0.05 [log (Ca ++) M] (Fig. 2e). It is evident
from Fig. 2 and Table 2 that all statins produced a right
shift in IC50 for CCRCs. The effects of statins are like
that of effects of verapamil, a standard calcium channel
blocker with a right shift [22, 23, 25].
Discussion
The findings of the study prove our assumptions that
statins may have inhibitory effects on voltage gated cal-
cium channels. These findings can be interpreted in
multiple ways. Like, if statins are used in combination
with other calcium channel blockers, especially for man-
agement of hypertension in obese who may have
hypercholestremia where statins may be advised for
management of concomitant hypercholestremia. Then
what could be the possible effects like additive or syner-
gistic, is yet to be answered on evidence based practice
of medicine. As it has been reported earlier that rhabdo-
myolysis and myositis occur with use of statins and
whereas there are reports of upregulation of L type cal-
cium channels in cell lines, hence, this study further
confirms that statins inhibit the voltage gated calcium
channels. This requires reassessment for dosimetry of
statins, particularly, in clinical environments where com-
bination of statins and calcium channel blockers are pre-
scribed together. More, chances of muscles’ weaknesses
or rhabdomyolysis should be reassessed in absence and
presence of a calcium channel blockers to prove its clin-
ical relevance. More, the use of statins may also be ques-
tioned for clinical conditions where maximum doses of
statins are recommended. Thus the findings of the
studies suggest that simvastatin and fluvastatin shifted
the calcium curves to right in relatively in less amount
i.e. 4.6 μg/ml and 9.61 μg/ml respectively. While Rosu-
vastatin and atorvastatin shifted the curves in presence
of 6.6 μg/ml and 23.1 μg/ml respectively. Logically
speaking, chances of adverse effects should be less with
fluvastatin as it shifted the curves to right in relatively
high concentration. Nevertheless, the tested statins fol-
low inhibition of voltage gated calcium channels that
warrants for reassessment of its dosimetry particularly in
presence of other voltage gated calcium channel
blockers like verapamil, diltiazem, amlodipine and ni-
fedipine in true clinical environments. Perhaps, reasses-
sing the doses of statins may be helpful to avoid
rhabdomyolysis or myositis that mostly appear in shape
of adverse effects of the statins rather than to go for its
withdrawal or blaming drugs that are already in the mar-
ket for a good cause.
Conclusions
Our findings suggest that current statins have relaxant
activity on smooth muscles that follow inhibitory effect
on voltage gated calcium channels that may explain the
possible rationale for gastrointestinal disorders and
muscle weakness that is reported with statins.
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